SA521431274B1 - مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 - Google Patents
مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1Info
- Publication number
- SA521431274B1 SA521431274B1 SA521431274A SA521431274A SA521431274B1 SA 521431274 B1 SA521431274 B1 SA 521431274B1 SA 521431274 A SA521431274 A SA 521431274A SA 521431274 A SA521431274 A SA 521431274A SA 521431274 B1 SA521431274 B1 SA 521431274B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
- 229940126027 positive allosteric modulator Drugs 0.000 title 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات وفقًا للصيغة (I)، وهي معدِّلات تفارغية إيجابية positive allosteric modulators من D1 وتكون بالتالي مفيدة كعوامل صيدلانية لمعالجة الأمراض التي تلعب فيها مستقبلات D1 دورًا.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183641 | 2019-07-01 | ||
| PCT/EP2020/068181 WO2021001286A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521431274B1 true SA521431274B1 (ar) | 2024-01-09 |
Family
ID=67137842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521431274A SA521431274B1 (ar) | 2019-07-01 | 2021-12-30 | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12358890B2 (ar) |
| EP (1) | EP3993795B1 (ar) |
| JP (1) | JP7618597B2 (ar) |
| KR (1) | KR102949226B1 (ar) |
| CN (1) | CN114008032B (ar) |
| AR (1) | AR119317A1 (ar) |
| AU (1) | AU2020299705B2 (ar) |
| BR (1) | BR112021022379A2 (ar) |
| CA (1) | CA3139622A1 (ar) |
| CL (1) | CL2021002949A1 (ar) |
| CO (1) | CO2021017740A2 (ar) |
| EC (1) | ECSP22007557A (ar) |
| IL (1) | IL289317B2 (ar) |
| MA (1) | MA56445A (ar) |
| MX (1) | MX2021015872A (ar) |
| MY (1) | MY210362A (ar) |
| PE (1) | PE20220373A1 (ar) |
| PH (1) | PH12021552819A1 (ar) |
| SA (1) | SA521431274B1 (ar) |
| SG (1) | SG11202112539XA (ar) |
| TW (1) | TWI842923B (ar) |
| UA (1) | UA130613C2 (ar) |
| WO (1) | WO2021001286A1 (ar) |
| ZA (1) | ZA202109194B (ar) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7591138B2 (ja) | 2020-10-07 | 2024-11-27 | イーライ リリー アンド カンパニー | ドーパミンｄ１受容体ポジティブアロステリック調節因子としてのフェニル－３，４－ジヒドロイソキノリン－２（１ｈ）－イル－エタン－１－オン誘導体 |
| BR112023018196A2 (pt) * | 2021-03-09 | 2023-12-12 | Lilly Co Eli | Uso de mevidalen e outros moduladores alostéricos positivos d1 para retardar a progressão da doença de parkinson |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009136330A (ru) | 2007-03-01 | 2011-04-10 | Янссен Фармацевтика Н.В. (Be) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| CN104010504B (zh) | 2011-11-03 | 2016-04-06 | 默沙东公司 | 作为mGluR2负变构调节剂的喹啉甲酰胺和喹啉甲腈的衍生物、组合物、及其用途 |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| US10105359B2 (en) * | 2014-10-08 | 2018-10-23 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| US10370355B2 (en) * | 2016-04-13 | 2019-08-06 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| WO2018167113A1 (en) * | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 CA CA3139622A patent/CA3139622A1/en active Pending
- 2020-06-29 MX MX2021015872A patent/MX2021015872A/es unknown
- 2020-06-29 KR KR1020227002603A patent/KR102949226B1/ko active Active
- 2020-06-29 MA MA056445A patent/MA56445A/fr unknown
- 2020-06-29 UA UAA202106080A patent/UA130613C2/uk unknown
- 2020-06-29 BR BR112021022379A patent/BR112021022379A2/pt unknown
- 2020-06-29 CN CN202080043673.9A patent/CN114008032B/zh active Active
- 2020-06-29 JP JP2021575050A patent/JP7618597B2/ja active Active
- 2020-06-29 SG SG11202112539XA patent/SG11202112539XA/en unknown
- 2020-06-29 AU AU2020299705A patent/AU2020299705B2/en active Active
- 2020-06-29 PE PE2021002217A patent/PE20220373A1/es unknown
- 2020-06-29 MY MYPI2021006863A patent/MY210362A/en unknown
- 2020-06-29 EP EP20735361.6A patent/EP3993795B1/en active Active
- 2020-06-29 WO PCT/EP2020/068181 patent/WO2021001286A1/en not_active Ceased
- 2020-06-29 US US17/621,871 patent/US12358890B2/en active Active
- 2020-06-29 PH PH1/2021/552819A patent/PH12021552819A1/en unknown
- 2020-06-29 IL IL289317A patent/IL289317B2/en unknown
- 2020-06-30 AR ARP200101852A patent/AR119317A1/es unknown
- 2020-06-30 TW TW109122034A patent/TWI842923B/zh active
-
2021
- 2021-11-08 CL CL2021002949A patent/CL2021002949A1/es unknown
- 2021-11-17 ZA ZA2021/09194A patent/ZA202109194B/en unknown
- 2021-12-23 CO CONC2021/0017740A patent/CO2021017740A2/es unknown
- 2021-12-30 SA SA521431274A patent/SA521431274B1/ar unknown
-
2022
- 2022-01-31 EC ECSENADI20227557A patent/ECSP22007557A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP22007557A (es) | 2022-02-25 |
| AR119317A1 (es) | 2021-12-09 |
| IL289317A (en) | 2022-02-01 |
| AU2020299705B2 (en) | 2026-03-19 |
| JP7618597B2 (ja) | 2025-01-21 |
| JP2022537994A (ja) | 2022-08-31 |
| CN114008032B (zh) | 2023-11-10 |
| MX2021015872A (es) | 2022-02-03 |
| IL289317B2 (en) | 2025-09-01 |
| CN114008032A (zh) | 2022-02-01 |
| MY210362A (en) | 2025-09-13 |
| US12358890B2 (en) | 2025-07-15 |
| TWI842923B (zh) | 2024-05-21 |
| CL2021002949A1 (es) | 2022-07-15 |
| BR112021022379A2 (pt) | 2022-03-08 |
| CO2021017740A2 (es) | 2022-01-17 |
| SG11202112539XA (en) | 2021-12-30 |
| MA56445A (fr) | 2022-05-11 |
| IL289317B1 (en) | 2025-05-01 |
| WO2021001286A1 (en) | 2021-01-07 |
| PH12021552819A1 (en) | 2022-09-28 |
| UA130613C2 (uk) | 2026-04-01 |
| EP3993795A1 (en) | 2022-05-11 |
| US20220251064A1 (en) | 2022-08-11 |
| EP3993795B1 (en) | 2026-04-22 |
| PE20220373A1 (es) | 2022-03-16 |
| KR20220029687A (ko) | 2022-03-08 |
| ZA202109194B (en) | 2023-11-29 |
| AU2020299705A1 (en) | 2021-12-09 |
| TW202115009A (zh) | 2021-04-16 |
| KR102949226B1 (ko) | 2026-04-06 |
| CA3139622A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ777871A (en) | Small molecule modulators of il-17 | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| PH12016500777A1 (en) | Compositions and methods for modulating farnesoid x receptors | |
| MX2020007853A (es) | Composiciones farmaceuticas para el tratamiento de fibrosis quistica. | |
| EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| GEP20207102B (en) | Sulfonamides as modulators of sodium channels | |
| UA109220C2 (uk) | Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| ECSP088854A (es) | Moduladores bencimidazolicos de vr1 | |
| MY181959A (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX362919B (es) | Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1]. | |
| SA521431274B1 (ar) | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 | |
| EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
| EA201991728A1 (ru) | Модуляторы аденозиновых рецепторов a | |
| ZA202305336B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
| MX385475B (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa | |
| EA202191053A1 (ru) | Соединения 2-формил-3-гидроксифенилоксиметила в качестве модулятора гемоглобина | |
| BR112019024708A2 (pt) | composições farmacêuticas de liberação prolongada retardada | |
| TN2013000241A1 (en) | Compositions and methods for modulating fxr |